Brain Tumors (Glioblastoma/Malignant Gliomas)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    VEGFR Expression 100 Bevacizumab (VEGF inhibitor):
    • Phase 2 (single agent) (recurrent disease): RR 28%, PFS at 6 mo 43% (1)
    • Phase 2, with irinotecan, RT: RR 38%, PFS at 6 mo 50% (1)
    • Phase 2: RR 35%, PFS at 6 mo 29% (single agent and RT) (FDA approved) (2)
    Sorafenib (VEGFR/PDGFR/RAS/RET inhibitor):
    • Phase 1, with RT: OS 18 mo (ND), 24 mo (recurrent disease)
    EGFR Amplification/overexpression  40 Erlotinib (EGFR inhibitor):
    • Phase 2, with temozolamide and RT
    Other topics in Targets by Organ Site